Fig. 9

Screening of potential antineoplastic drugs based on prognostic miRNAs and risk group. A–C hsa-mir-100, hsa-mir-125b-2 and hsa-mir-145 were positively correlated with sensitivity to dromostanolone propionate, lovastatin and zoledronate, respectively. D hsa-mir-221 was negatively correlated with sensitivity to SR16157. E–L Eight drugs with higher sensitivity in the high-risk group